Early trial data supports neurodegenerative disease-modifying drug
Drug Discovery World
MARCH 15, 2024
The Phase Ib study examined the safety, tolerability and pharmacokinetics of twice-daily oral doses of ALX-001 in 32 heathy adult participants aged 50-80. All doses were well-tolerated and there were no serious adverse events. The findings were presented at the AD/PD 2024 Conference in Lisbon.
Let's personalize your content